CoChat

Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer‐derived CD133‐positive cells

Hsu, Han‐Shui, Huang, Pin‐I, Chang, Yuh‐Lih, Tzao, Ching, Chen, Yi‐Wei, Shih, Hsin‐Chin, Hung, Shih‐Chieh, Chen, Yu‐Chih, Tseng, Ling‐Ming, Chiou, Shih‐Hwa · 2011 · Cancer
Cited by 112

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Signal transducer and activator of transcription 3 (STAT3) signaling reportedly promotes tumor malignancy and recurrence in nonsmall cell lung cancer (NSCLC). It was demonstrated previously that the STAT3 pathway maintains the tumorigenicity and therapeutic resistance of malignant tumors as well as cancer stem cells (CSCs). The objective of the current study was to investigate the effect of the strong STAT3 inhibitor, cucurbitacin I, in prominin‐1 (CD133)‐positive lung cancer cells. METHODS: CD133‐positive and CD133‐negative NSCLC‐derived cells were isolated from 7 patients with NSCLC. CD133‐positive NSCLC cells that were treated with or without cucurbitacin I were evaluated for their expression of phosphorylated STAT3 (p‐STAT3), tumorigenicity, stemness properties, and resistance to chemotherapeutic drugs and ionizing radiation. RESULTS: Compared with parental or CD133‐negative NSCLC cells, CD133‐positive NSCLC cells had greater tumorigenicity, greater radioresistance, and higher expression of octamer‐binding transcription factor 4 (Oct‐4), Nanog homeobox, and sex‐determining region Y, box 2 (Sox2) at high p‐STAT3 levels. Cucurbitacin I treatment at 100 nM effectively abrogated STAT3 activation, tumorigenic capacity, sphere formation ability, radioresistance, and chemoresistance in CD133‐positive NSCLC cells. Microarray data suggested that cucurbitacin I inhibited the stemness gene signature of CD133‐positive NSCLC cells and facilitated the differentiation of CD133‐positive NSCLC cells into CD133‐negative NSCLC cells. It is noteworthy that 150 nM cucurbitacin I effectively blocked STAT3 signaling and downstream survival targets, such as B‐cell chronic lymphocytic leukemia/lymphoma 2 (Bcl‐2) and Bcl‐2‐like 1 (Bcl‐xL) expression and induced apoptosis in CD133‐positive NSCLC cells. Finally, xenotransplantation experiments revealed that cucurbitacin I plus radiotherapy or chemotherapeutic drugs significantly suppressed tumorigenesis and improved survival in NSCLC‐CD133‐positive‐transplanted, immunocompromised mice. CONCLUSIONS: Targeting STAT3 signaling in CD133‐positive NSCLC cells with cucurbitacin I suppressed CSC‐like properties and enhanced chemoradiotherapy response. The potential of cucurbitacin I should be verified further in future anti‐CSC therapy. Cancer 2011. © 2011 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.25869

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 112

Metadata

Authors
Hsu, H., Huang, P., Chang, Y., Tzao, C., Chen, Y., Shih, H., Hung, S., Chen, Y., Tseng, L., & Chiou, S.
Venue
Cancer
Publisher
Wiley
Published
2011-01-10
Volume
117
Issue
13
Pages
2970-2985
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1987678124
Cited by
112
References
5
FWCI
6.48
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.